Abstract P02-03: Phase Ia/Ib dose-escalation study of ABL001 (CTX-009, bispecific antibody targeting DLL4 and VEGF-A) as a single agent in patients with advanced solid tumors
Lee, Jeeyun, Kim, SeungTae, Hong, JungYong, Park, YoungSuk, Park, JoonOh, Kang, WonKi, Lee, Keun-Wook, Kim, Jin Won, Kim, Ji-Won, Kim, Se Hyun, Ha, Eunsin, Lee, Sangmi, Kim, JongRan, You, Weon-Kyoo
Published in Molecular cancer therapeutics (01.12.2021)
Published in Molecular cancer therapeutics (01.12.2021)
Get full text
Journal Article
Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL)
Bartlett, Nancy L., Sehn, Laurie Helen, Assouline, Sarit E., Bosch, Francesc, Magid Diefenbach, Catherine S., Flinn, Ian, Hong, Jungyong, Kim, Wonseog S, Matasar, Matthew J., Nastoupil, Loretta J., Schuster, Stephen J, Shadman, Mazyar, Yoon, Sung-Soo, Bender, Brendan, Kwan, Antonia, Cunlin, Wang, Wei, Michael C., Yin, Shen, Yousefi, Kasra, Budde, L. Elizabeth
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article